---
title: "Lysergide (DT120) in Generalized anxiety disorder: Serotonin-Norepinephrine reuptake inhibitors"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Serotonin-Norepinephrine reuptake inhibitors. Topics: NICE guideline: an alternative SSRI or an SNRI after sertraline, CANMAT guideline: duloxetine and venlafaxine XR as first-line agents, BAP guideline: SNRIs as alternative initial treatments, FDA-approved GAD indication: venlafaxine extended-release, and 9 further topics. 13 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/serotonin-norepinephrine-reuptake-inhibitors"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Serotonin-Norepinephrine reuptake inhibitors

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Serotonin-Norepinephrine Reuptake Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

### NICE guideline: an alternative SSRI or an SNRI after sertraline

> “If sertraline is ineffective, offer an alternative SSRI or a serotonin–noradrenaline reuptake inhibitor (SNRI), taking into account the following factors:”
> “tendency to produce a withdrawal syndrome (especially with paroxetine and venlafaxine)”
> “the risk of suicide and likelihood of toxicity in overdose (especially with venlafaxine)”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.3-2"></a>

### CANMAT guideline: duloxetine and venlafaxine XR as first-line agents

> “an SNRI such as duloxetine or venlafaxine XR, or other antidepressant such as agomelatine.”
> “In head-to-head comparisons, the efficacy of SSRIs and SNRIs appear to be similar”
> “Some data suggest that escitalopram may be less effective than venlafaxine XR”
> “Efficacy of venlafaxine was similar to pregabalin in one RCT”
> “If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.3-3"></a>

### BAP guideline: SNRIs as alternative initial treatments

> “SNRIs and pregabalin may be considered as alternative initial treatments if SSRIs are judged to be unsuitable [A]”
> “The SNRIs duloxetine and venlafaxine have proven efficacy in short-term and long-term treatment of generalised anxiety disorder”
> “Although the tolerability profiles of SSRIs and SNRIs in patients with anxiety disorders are not established fully, systematic reviews of studies in depressed patients suggest that duloxetine and venlafaxine may be less well tolerated than the SSRIs”
> “Both duloxetine and venlafaxine have been associated with discontinuation symptoms after abrupt withdrawal”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### FDA-approved GAD indication: venlafaxine extended-release

> “Effexor XR is indicated in adults for the treatment of:”
> “Generalized Anxiety Disorder (GAD) [see Clinical Studies (14.2)]”
> “For most patients, the recommended starting dose for Effexor XR is 75 mg per day, administered in a single dose. For some patients, it may be desirable to start at 37.5 mg per day for 4 to 7 days to allow new patients to adjust to the medication before increasing to 75 mg per day. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day.”
> “The efficacy of Effexor XR as a treatment for Generalized Anxiety Disorder (GAD) was established in two 8-week, placebo-controlled, fixed-dose studies (75 to 225 mg per day), one 6-month, placebo-controlled, flexible-dose study (75 to 225 mg per day), and one 6-month, placebo-controlled, fixed-dose study (37.5, 75, and 150 mg per day) in adult outpatients meeting DSM-IV criteria for GAD.”
> “A dose-response relationship for effectiveness in GAD was not clearly established in the 75 to 225 mg per day dose range studied.”

Source: [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

### Venlafaxine extended-release: HAM-A results of the four adult GAD studies

| Study and treatment group | LS mean change from baseline (SE) | Placebo-subtracted difference (95% CI) |
| --- | --- | --- |
| Study 1, venlafaxine XR 75 mg | “-11.1 (0.95)” | “-1.5 (-3.8, 0.8)” |
| Study 1, venlafaxine XR 150 mg | “-11.7 (0.87)” | “-2.2 (-4.5, 0.1)” |
| Study 1, venlafaxine XR 225 mg | “-12.1 (0.81)” | “-2.6 (-4.9, -0.3)” |
| Study 1, placebo | “-9.5 (0.85)” |  |
| Study 2, venlafaxine XR 75 mg | “-10.6 (0.82)” | “-2.6 (-4.6, -0.5)” |
| Study 2, venlafaxine XR 150 mg | “-9.8 (0.86)” | “-1.7 (-3.8, 0.3)” |
| Study 2, placebo | “-8.0 (0.73)” |  |
| Study 3, venlafaxine XR 37.5 mg | “-13.8” | “-2.8 (-5.1, -0.6)” |
| Study 3, venlafaxine XR 75 mg | “-15.5” | “-4.6 (-6.9, -2.3)” |
| Study 3, venlafaxine XR 150 mg | “-16.4” | “-5.5 (-7.8, -3.1)” |
| Study 3, placebo | “-11.0” |  |
| Study 4, venlafaxine XR 75-225 mg | “-13.4 (0.79)” | “- 4.7 (-6.6, -2.9)” |
| Study 4, placebo | “-8.7 (0.70)” |  |

Source: [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

### FDA-approved GAD indication: duloxetine

> “Generalized anxiety disorder in adults and pediatric patients 7 years of age and older”
> “For most adults less than 65 years of age with GAD, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to CYMBALTA before increasing to 60 mg once daily. While a 120 mg once daily dosage was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit.”
> “The efficacy of CYMBALTA in the treatment of generalized anxiety disorder (GAD) was established in 1 fixed-dose randomized, double-blind, placebo-controlled trial and 2 flexible-dose randomized, double-blind, placebo-controlled trials in adult outpatients between 18 and 83 years of age meeting the DSM-IV criteria for GAD (Studies GAD-1, GAD-2, and GAD-3, respectively).”
> “In all 3 trials, CYMBALTA demonstrated superiority over placebo as measured by greater improvement in the Hamilton Anxiety Scale (HAM-A) total score (see Table 8) and by the Sheehan Disability Scale (SDS) global functional impairment score.”
> “Patients treated with CYMBALTA (N=151) demonstrated significantly greater improvement compared with placebo (N=140) on mean change from baseline to endpoint as measured by the HAM-A total score (see Table 8).”

Source: [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

### Duloxetine: relapse prevention in responders

> “Four hundred and twenty-nine patients who responded to open-label treatment [defined as meeting the following criteria at weeks 24 and 26: a decrease from baseline HAM-A total score by at least 50% to a score no higher than 11, and a Clinical Global Impressions of Improvement (CGI-Improvement) score of 1 or 2] were randomly assigned to continuation of CYMBALTA at the same dosage (N=216) or to placebo (N=213) and were observed for relapse.”
> “Patients taking CYMBALTA experienced a statistically significantly longer time to relapse of GAD than did patients taking placebo”

Source: [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

### FDA approval history and response and remission with venlafaxine and duloxetine

> “Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for the treatment of GAD, MDD, panic disorder, and social anxiety disorder.”
> “In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms”
> “and was the first FDA-approved antidepressant for the treatment of GAD in this age group.”
> “Response rates in patients receiving venlafaxine XR were 69% compared to 46% in patients randomized to placebo (p<0.001)”
> “These trials have recently been subjected to a meta-analysis which revealed superior remission rates for duloxetine (n=2,399, RR = 1.60, 95% CI: 1.43–1.80) and greater improvement in HAM-A scores (n=1,135, MD = 3.34, 95% CI: 2.37–4.32), while finding no differences in discontinuation rates between placebo and duloxetine”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.3-9"></a>

### Network meta-analysis: duloxetine and venlafaxine

> “Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13)”
> “venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89)”
> “were more efficacious than placebo with relatively good acceptability.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.3-10"></a>

### SNRIs compared with SSRIs: efficacy and sexual adverse effects

> “SNRIs are very similar to SSRIs in their mechanism of action, side effects, and efficacy rates (Hedges’ g = 0.42, SD=0.12, p<0.0001)”
> “though there is some evidence that SNRIs are associated with less sexual dysfunction side effects than SSRIs”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.3-11"></a>

### Adverse reactions and discontinuation with venlafaxine extended-release

> “The most commonly observed adverse reactions in the clinical study database in Effexor XR treated patients in MDD, GAD, SAD, and PD (incidence ≥5% and at least twice the rate of placebo) were: nausea (30.0%), somnolence (15.3%), dry mouth (14.8%), sweating (11.4%), abnormal ejaculation (9.9%), anorexia (9.8%), constipation (9.3%), impotence (5.3%), and decreased libido (5.1%).”
> “Combined across short-term, placebo-controlled premarketing studies for all indications, 12% of the 3,558 patients who received Effexor XR (37.5-225 mg) discontinued treatment due to an adverse experience, compared with 4% of the 2,197 placebo-treated patients in those studies.”
> “In controlled trials, there were dose-related increases in systolic and diastolic blood pressure, as well as cases of sustained hypertension”
> “Monitor blood pressure before initiating treatment with Effexor XR and regularly during treatment.”
> “Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment.”

Source: [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf)

<a id="topic-2.2.2.1.3-12"></a>

### Adverse reactions and discontinuation with duloxetine

> “Approximately 13.7% (139/1018) of the CYMBALTA-treated patients in placebo-controlled adult trials for GAD discontinued treatment due to an adverse reaction, compared with 5% (38/767) for placebo-treated patients.”
> “Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included nausea (CYMBALTA 3.3%, placebo 0.4%), and dizziness (CYMBALTA 1.3%, placebo 0.4%).”
> “The most commonly observed adverse reactions in CYMBALTA-treated patients in all the pooled adult populations (i.e., MDD, GAD, DPNP, FM, OA, and CLBP) (incidence of at least 5% and at least twice the incidence in placebo-treated patients) were nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis.”
> “There have been reports of hepatic failure, sometimes fatal, in patients treated with CYMBALTA.”
> “Following abrupt or tapered discontinuation in adult placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in CYMBALTA-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue.”

Source: [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf)

<a id="topic-2.2.2.1.3-13"></a>

### Relapse after discontinuation: meta-analysis of relapse prevention trials, SNRI subgroup

| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
| --- | --- | --- |
| SNRI | “3” | “5.03 (1.31 to 19.40)” |

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
